Loomis Sayles, an investment management company, recently released its third-quarter 2025 investor letter for its Small Cap Value Fund. The letter highlighted the strong performance of US equities in the third quarter, attributing it to easing tariff concerns, a pro-growth budget passed by the U.S. Congress, and anticipation of further rate cuts by the Federal Reserve. The fund returned 6.21% in the quarter, compared to 12.60% for the Russell 2000 Value Index.
One of the stocks mentioned in the investor letter was Haemonetics Corporation (NYSE:HAE), a medical technology company based in Boston, Massachusetts. The one-month return of Haemonetics Corporation (NYSE:HAE) was -0.92%, and its shares gained 3.36% over the last 52 weeks. As of December 24, 2025, Haemonetics Corporation (NYSE:HAE) stock closed at $80.01 per share, with a market capitalization of $3.855 billion.
In the investor letter, Loomis Sayles Small Cap Value Fund discussed Haemonetics Corporation (NYSE:HAE) and its performance in the third quarter of 2025. The fund mentioned that stock selection measures trailed the index due to a style mismatch with their high-quality approach. Haemonetics Corporation (NYSE:HAE), along with Alight, Inc. and Kyndryl Holdings Incorporated, detracted the most from the fund’s performance.
Despite the challenges faced by Haemonetics Corporation (NYSE:HAE), the company is not on the list of 30 Most Popular Stocks Among Hedge Funds. However, 36 hedge fund portfolios held Haemonetics Corporation (NYSE:HAE) at the end of the third quarter, which was an increase from the previous quarter. In the second quarter of fiscal 2026, Haemonetics Corporation (NYSE:HAE) reported a revenue of $327 million, marking a 5% decline in reported revenue.
While Haemonetics Corporation (NYSE:HAE) shows potential as an investment, Loomis Sayles believes that certain AI stocks offer greater upside potential with less downside risk. Investors looking for undervalued AI stocks that could benefit from Trump-era tariffs and the onshoring trend are encouraged to explore the best short-term AI stock.
In conclusion, Loomis Sayles Small Cap Value Fund’s investor letter for the third quarter of 2025 provides insights into the fund’s performance and highlights stocks like Haemonetics Corporation (NYSE:HAE). Despite challenges, the fund continues to analyze investment opportunities to maximize returns for its investors.
